Medivation Inc  

(Public, NASDAQ:MDVN)   Watch this stock  
Find more results for mdvn
+1.74 (4.44%)
Real-time:   2:47PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 39.21 - 41.12
52 week 38.08 - 70.79
Open 39.36
Vol / Avg. 1.20M/2.45M
Mkt cap 6.69B
P/E 26.08
Div/yield     -
EPS 1.57
Shares 163.39M
Beta 0.96
Inst. own 95%
Nov 4, 2015
Q3 2015 Medivation Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 17, 2015
Medivation Inc at Morgan Stanley Healthcare Conference
Aug 6, 2015
Q2 2015 Medivation Inc Earnings Call - Webcast
Aug 6, 2015
Q2 2015 Medivation Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 14.70% 38.91%
Operating margin 26.07% 39.67%
EBITD margin - 40.41%
Return on average assets 11.17% 42.39%
Return on average equity 20.75% 105.07%
Employees 485 -
CDP Score - -


525 Market St Fl 36
SAN FRANCISCO, CA 94105-2747
United States - Map
+1-415-5433470 (Phone)
+1-415-5433411 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.

Officers and directors

Kim D. Blickenstaff Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
David T. Hung M.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Richard A. Bierly Chief Financial Officer
Age: 59
Bio & Compensation  - Reuters
Andrew Kenneth William Powell Senior Vice President, General Counsel, Corporate Secretary
Age: 57
Bio & Compensation  - Reuters
Lily Yang Principal Accounting Officer, Vice President - Finance & Accounting
Age: 43
Bio & Compensation  - Reuters
Joseph M. Lobacki Chief Commercial Officer
Age: 57
Bio & Compensation  - Reuters
Lynn Seely M.D. Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
C. Patrick Machado J.D. Director
Age: 51
Bio & Compensation  - Reuters
Kathryn E. Falberg Independent Director
Age: 54
Bio & Compensation  - Reuters
Dawn Svoronos Independent Director
Age: 61
Bio & Compensation  - Reuters